QIAGEN partners to develop novel companion diagnostic in lung cancer
Apr 13 2016

QIAGEN partners to develop novel companion diagnostic in lung cancer

Collaboration with Mirati Therapeutics targets MET gene mutations to personalize treatment

Hilden, Germany, and Germantown, Maryland, April 13, 2016 QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with Mirati Therapeutics, Inc. (NASDAQ: MRTX) to co-develop and commercialize a companion diagnostic test to guide the use of Mirati’s glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

“We are pleased to partner with Mirati to commercialize a standardized companion diagnostic paired with glesatinib, a compound now in Phase II trials for NSCLC patients with cancer-driving MET alterations. Delivering insights on these clinically actionable variants holds potential to significantly improve clinical outcomes,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “This companion diagnostic for glesatinib is the initial effort under a master collaboration agreement and we continue to discuss potential future projects across various sample types and platforms, such as PCR and NGS, to further expand targeted diagnostic capabilities in this arena.”

"As Mirati advances therapies targeting genetic alterations responsible for driving cancer growth, we are pleased to partner with QIAGEN, which has developed and marketed regulator-approved companion diagnostics for a wide range of genomic biomarkers,” said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "Mirati’s targeted oncology programs depend on companion diagnostics to select the patients who will benefit the most from treatment.”

QIAGEN is at the forefront globally in developing companion diagnostics using genomic insights to guide the selection of medicines for cancer and other diseases. The company already markets Personalized Healthcare kits covering about 30 biomarkers, spanning a variety of automation platforms and biological sample types. QIAGEN continues to expand its pipeline of Sample to Insight technologies for personalized healthcare and intends to submit more tests for regulatory clearance or approval. Numerous co-development partnerships are underway with leading pharmaceutical and biotech companies, some publicly disclosed but most not individually announced.

 

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). 


SOCIAL SHARING

Share this page